Watch your wealth rise with the power of AI research tools only with TradeZing PLUS!
Subscribe NowTrade together with legendary hedge fund manager Larry Benedict every morning before the bell
What is Trade the Day?
Get ahead of the market curve each trading day with Larry Benedict, a distinguished Barron’s Top 100 hedge fund manager and the founder of the Opportunistic Trader ETF (WZRD). With his analyst, Eric Shamilov, Larry provides live, pre-market trading insights and strategic analysis, equipping you with the knowledge to make smart trading decisions.
Subscribe now for exclusive advantages and benefits!
May 6, 2024
15 mins ago
MILAN, Italy and NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) — Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, announces that it held its Ordinary and Extraordinary Shareholders’ Meeting on May 2, 2024. At the Ordinary and Extraordinary Shareholders’ Meeting, the Company’s shareholders approved the appointment of five directors to the Company’s Board of Directors, effective as of May 2, 2024, including four new members. The new members of the Board include: John L. Cantello, Ph.D., Lauren H. Chung, Ph.D., Armon R. Sharei, Ph.D. and Todd Wider, M.D., and Pierluigi Paracchi, Chief Executive Officer, will continue to serve on the Board as Chairman.
175906
News
May 6, 2024
18 mins ago
Will the company’s turnaround plan work?
175908
News
LAFAYETTE, Ind., April 24, 2024 (GLOBE NEWSWIRE) — Wabash (NYSE: WNC), the innovation leader of connected solutions for the transportation, logistics and distribution industries, today reported results for the quarter ended March 31, 2024.
Continue ReadingCopied
May 6, 2024
15 mins ago
MILAN, Italy and NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) — Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, announces that it held its Ordinary and Extraordinary Shareholders’ Meeting on May 2, 2024. At the Ordinary and Extraordinary Shareholders’ Meeting, the Company’s shareholders approved the appointment of five directors to the Company’s Board of Directors, effective as of May 2, 2024, including four new members. The new members of the Board include: John L. Cantello, Ph.D., Lauren H. Chung, Ph.D., Armon R. Sharei, Ph.D. and Todd Wider, M.D., and Pierluigi Paracchi, Chief Executive Officer, will continue to serve on the Board as Chairman.
GNTA
175906
News
May 6, 2024
18 mins ago
Will the company’s turnaround plan work?
SBUX
175908
News
Introducing Audio Rooms: Engage in real-time discussions on community or news topics with fellow users. Each article or post can instantly create its exclusive audio room, facilitating conversations about subjects directly tied to the article or community post.
Audio Room Title:
Someone already created an audio of this feed.
Join the room
Seeking Alpha
Bezinga
Market Rebellion
Motley Fool
And More!
Subscribe now for exclusive advantages and benefits!
1 Comment
Most Voted
11 days ago
That sounds like an interesting update! What were the highlights from Wabash’s first quarter resultsthat caught YOUR eye?